Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Semaglutide demonstrated a clear clinical advantage with significant weight loss outcomes in phase 3 trials, achieving a mean body-weight change of -14.9% at 68 weeks compared to -2.4% with placebo. The evidence is robust, with multiple pivotal studies showing consistent results across different populations, including those with type 2 diabetes. The active-comparator evidence against liraglutide further supports its efficacy, with semaglutide showing superior outcomes in weight loss and related health metrics.
Cost effectiveness
Semaglutide is considered marginally cost-effective with an ICER of $66,355 per QALY gained, which is defensible under common thresholds. However, the economic model is sensitive to assumptions about treatment duration and patient adherence, indicating that while it is cost-effective, the value proposition may vary significantly based on real-world application.
Quality of life
The evidence for HRQoL improvements is moderate, with semaglutide showing positive changes in validated instruments like SF-36 and IWQOL-Lite-CT. While improvements were noted, the magnitude of change was modest and not consistently statistically significant across all trials. This indicates a beneficial impact on quality of life, but the evidence is not as compelling as the weight loss data.
Supporting Domains
Safety and Adverse Effects
Semaglutide has a very good safety profile, with gastrointestinal adverse events being the most common but manageable. The rates of serious adverse events are lower compared to liraglutide, and while there are warnings for potential severe effects, the overall tolerability is acceptable, supporting its use in the target population.
Comparator Selection
The comparator selection for semaglutide included appropriate standards of care, primarily placebo plus lifestyle interventions, and active comparators like liraglutide. While the evidence is strong for registration trials, the lack of more recent active-comparator data against newer agents like tirzepatide presents a limitation for current payer decision-making.
Patient Population and Subgroups
The trial populations included diverse groups, such as those with type 2 diabetes and East Asian participants, enhancing generalizability. However, there are some concerns regarding the representation of lower-BMI groups and the exclusion of certain diabetes populations, which slightly limits the overall applicability of the findings.
Care Pathway Integration
Semaglutide integrates well into existing care pathways as an adjunct to diet and exercise. However, the implementation requires structured pathways and specialist oversight, which may pose challenges in some healthcare systems. The evidence on operational impacts and training needs is limited, but the integration is generally feasible.
Resource Use and Cost Implications
The resource implications of semaglutide are significant, with high costs associated with treatment. While it shows potential for cost-effectiveness in modeled scenarios, real-world budget impacts are concerning, particularly given the high annual treatment costs and the limited number of patients who could be treated without exceeding budget thresholds.
Evidence Quality and Robustness
The evidence base for semaglutide is strong, supported by multiple phase 3 RCTs with low bias and consistent results. However, some reliance on modeled economic data and observational studies introduces moderate uncertainty, particularly regarding long-term outcomes and real-world effectiveness.
Uncertainty, Sensitivity, and Broader Impacts
While there is moderate uncertainty regarding treatment duration and the long-term maintenance of benefits, the context of unmet need and the potential for significant health improvements in the target population provide a favorable backdrop for semaglutide’s use. However, access issues and economic constraints remain significant concerns.
